Radiotherapy Shows Promise in Preventing Lifelong Arm Swelling After Breast Cancer Treatment
A groundbreaking new treatment approach is offering hope for breast cancer patients, potentially eliminating the dreaded side effect of lifelong arm swelling. This innovative strategy could significantly improve the quality of life for those undergoing treatment for this prevalent disease.
Currently, a standard part of breast cancer surgery involves removing small glands located under the arm. While this procedure is crucial for cancer removal, it can inadvertently disrupt the body’s natural lymphatic drainage system. This disruption can lead to a buildup of fluid, causing persistent swelling in the arm, a condition known as lymphoedema. The statistics are stark: approximately one in five breast cancer patients develop lymphoedema, with the risk escalating to as high as one in two for those whose glands are removed.
However, emerging research suggests a safer alternative. Instead of surgically removing these vital glands, doctors could potentially treat the area with radiotherapy. This method aims to preserve the integrity of the lymphatic system, thereby drastically reducing the risk of lymphoedema.
Study Findings: Radiotherapy vs. Surgical Removal of Glands
A significant study presented at the 15th European Breast Cancer Conference in Barcelona has provided compelling evidence for this new approach. The research meticulously compared two groups of patients whose cancer had spread to nearby glands: one group underwent the standard surgical removal of these glands, while the other received radiotherapy.
The trial involved over 270 participants. The results after two years were encouraging:
- Radiotherapy Group: Lymphoedema developed in just under 18 per cent of patients.
- Surgical Group: More than 26 per cent of patients experienced lymphoedema.
Crucially, the study also found that the cancer outcomes were comparable between the two groups. The radiotherapy group reported no cancer recurrences, while the surgical group had one recurrence.
Expert Perspectives and Future Implications
Professor Amparo Garcia-Tejedor from Bellvitge University Hospital, the lead author of the study, highlighted the potential impact of these findings. “If the study confirms the safety and effectiveness of radiotherapy instead of surgery, the implications for both patients and clinicians could be substantial,” she stated. “For patients, the main benefit would be an improvement in quality of life.”
Professor Garcia-Tejedor further commented on the evolution of cancer treatment, noting a gradual shift away from overly aggressive surgical interventions. “Now, the goal is to save lives without increasing adverse effects. Our findings suggest that surgery may be unnecessary in a substantial proportion of patients and that a strategy of de-escalation should be explored,” she explained.
Cautions and Next Steps
While these initial findings are highly promising, experts are urging a degree of caution. Patients are advised not to alter their treatment plans based solely on these early results. A larger, more comprehensive phase III trial is currently underway to further validate the safety and efficacy of radiotherapy as a primary treatment for lymph node management in breast cancer.
Dr. Maria Laplana-Torres, a radiation oncologist involved in the research, acknowledged that radiotherapy did lead to more short-term skin-related side effects, such as redness and peeling. However, she emphasised that these were generally temporary and manageable. After two years of follow-up, no significant differences were observed in terms of arm movement or overall quality of life between the two groups, with outcomes leaning slightly in favour of radiotherapy.
The main trial has already recruited over 500 patients, and results are anticipated in approximately three more years, following extended follow-up periods.
Dr. Simon Vincent, chief scientific officer at Breast Cancer Now, who was not directly involved in the study, welcomed the research. “While this early research suggests that radiotherapy may be a suitable alternative treatment to avoid unwanted side effects like lymphoedema, we hope to see longer follow-up of patients to fully understand its safety and effectiveness,” he commented.
The Broader Impact of Lymphoedema
Lymphoedema is a significant health concern, affecting over 200,000 people in the UK, with cancer treatment being a primary cause. Breast cancer itself remains the most common cancer diagnosed in women in the UK, with approximately 55,000 new cases identified each year. The development of treatments that mitigate debilitating side effects like lymphoedema is therefore of paramount importance in improving patient outcomes and long-term well-being. This new radiotherapy approach represents a vital step forward in that direction.
